Literature DB >> 6603291

Malignant hypertension in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency.

W M Hague, J W Honour.   

Abstract

Two brothers, aged 20 and 12, with the 11 beta-hydroxylase deficient form of congenital adrenal hyperplasia, are presented. They had refused treatment for the previous four years until the younger was admitted with malignant hypertension, partial blindness and evidence of myocardial damage. The elder was therefore admitted for assessment and found to have less severe hypertension. Gas liquid chromatographic analysis of the steroids in urine from each revealed a possible difference in the enzyme defect between the two brothers--the younger having a complete, while the elder had only a partial block. Family studies have confirmed no association with the HLA locus.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603291     DOI: 10.1111/j.1365-2265.1983.tb02880.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

2.  Mineralocorticoid hypertension.

Authors:  Vishal Gupta
Journal:  Indian J Endocrinol Metab       Date:  2011-10

Review 3.  Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia.

Authors:  Mattia Barbot; Pierluigi Mazzeo; Martina Lazzara; Filippo Ceccato; Carla Scaroni
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-01       Impact factor: 6.055

4.  A Novel Mutation in the CYP11B1 Gene Causes Steroid 11β-Hydroxylase Deficient Congenital Adrenal Hyperplasia with Reversible Cardiomyopathy.

Authors:  Mohammad A Alqahtani; Ayed A Shati; Minjing Zou; Ali M Alsuheel; Abdullah A Alhayani; Saleh M Al-Qahtani; Hessa M Gilban; Brain F Meyer; Yufei Shi
Journal:  Int J Endocrinol       Date:  2015-07-22       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.